Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130286 | 1.00 | CA2 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL1231221 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL16970147 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL5173608 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL1857092 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL16969741 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL16970260 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL16969979 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL16970151 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL16892639 | 0.98 | GRIK1 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150240272-A1 | LACTATE PRODUCTION PROCESS | PLAXICA LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| WO-2014045036-A1 | LACTATE PRODUCTION PROCESS | PLAXICA LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
| EP-1585518-B9 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1585757-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1585518-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7666659-B2 | Process for producing optically active 3-hydroxypropionic ester derivative | KANEKA CORPORATION (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20100016627-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE | KANEKA CORPORATION (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1585518-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1585518-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | disclosed |
| EP-1568679-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE | KANEKA CORPORATION (JP) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005032550-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1509218-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004052919-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| WO-2003101442-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | CA2 4828/4885MAPK1 3094/4885GRIK1 4545/4885 |
| US-20050222412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | CA2 4860/4885MAPK1 3587/4885GRIK1 4719/4885 |
| US-20100016627-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE | HPD, GRHPR, PAH | CA2 462/4885MAPK1 3054/4885GRIK1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.